Investigational drug · Phase 3
NCX 470
Also called: NCX 470 0.1%
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Open Angle Glaucoma, Ocular Hypertension.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
4
Any phase or sponsor naming "NCX 470"
First trial start
2020
Nov 9, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NCX 470", any sponsor or status.
Conditions studied
As listed on its trial records.
- Open Angle Glaucoma
- Ocular Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Glaucoma · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "NCX 470" as an intervention, largest first.
- MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT04630808 · 696 participants · Start Nov 9, 2020 · Primary completion Apr 11, 2025
Drug: NCX 470 0.1%; Latanoprost 0.005% · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Chandler, Arizona; Phoenix, Arizona · 88 sites in all
- Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT04445519 · 691 participants · Start Jun 1, 2020 · Primary completion Sep 16, 2022
Drug: NCX 470 0.065% (initial phase of trial); Latanoprost 0.005% (initial phase of trial) and 3 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT03657797 · 656 participants · Start Aug 1, 2018 · Primary completion Aug 23, 2019
Drug: NCX 470; Latanoprost 0.005% · For: Glaucoma, Open-Angle; Hypertension, Ocular
Sites: Austin, Texas
- Aqueous Humor Dynamics of NCX 470 Ophthalmic SolutionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT05938699 · 18 participants · Start Dec 12, 2023 · Primary completion Mar 17, 2025
Drug: NCX 470; Placebo · For: Open Angle Glaucoma
Sites: Rochester, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
- A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study.
Mansberger SL, Fechtner R, Lopez K, et al. · Contemp Clin Trials 2024
- A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study.
Fechtner R, Mansberger S, Branch J, et al. · Am J Ophthalmol 2024
- NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs.
Galli C, Bastia E, Hubatsch DA, et al. · J Ocul Pharmacol Ther 2024
- NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina.
Sgambellone S, Marri S, Villano S, et al. · Transl Vis Sci Technol 2023
- Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review.
Moshegov S, Kerr NM · Expert Opin Investig Drugs 2023
- NCX 470 Restores Ocular Hemodynamics and Retinal Cell Physiology After ET-1-Induced Ischemia/Reperfusion Injury of Optic Nerve and Retina in Rabbits.
Bastia E, Sgambellone S, Lucarini L, et al. · J Ocul Pharmacol Ther 2022
Also in development for Open Angle Glaucoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.